Robert Proudfoot

Mary Hames is a seasoned Medical Affairs executive with a proven track record of leading high-performing teams and delivering strategic impact across rare disease, diagnostics, and oncology. With a foundation in biochemical genetics and over a decade of industry experience, she has played pivotal roles in clinical operations, launch preparedness, and cross-functional leadership. Known for her ability to navigate complex medical landscapes, Mary has successfully built and led medical teams, advanced companion diagnostics, and driven field strategy across multiple therapeutic areas. Her leadership is marked by scientific rigor, operational excellence, and a deep commitment to improving outcomes for patients with rare and life-threatening conditions.

As a physician-scientist and biotech executive, I have dedicated my career to bridging the gap between groundbreaking medical research and commercial success. From securing multimillion-dollar funding to leading strategic M&A deals, my passion lies in driving healthcare innovation that delivers real-world impact. Here is my biography.

Maryam Nourbakhsh is a seasoned project management leader with over 18 years of experience in the pharmaceutical and healthcare industries, specializing in strategic operations, clinical quality, and global regulatory compliance. She has a proven track record of driving complex initiatives, optimizing resource allocation, and implementing data-driven decision-making frameworks to enhance portfolio planning and operational efficiency. Currently serving as Director of Project Management at Bristol Myers Squibb, she spearheads innovative methodologies, fosters cross-functional collaboration, and ensures alignment with corporate objectives. With expertise spanning oncology, immunology, and hematology, Maryam has successfully led high-impact projects at leading pharmaceutical organizations, leveraging her knowledge in clinical trials, governance structures, and process improvement. Holding an MBA in Pharmaceutical Marketing and certifications in Lean Six Sigma and Change Management, she is a strategic thinker committed to innovation, operational excellence, and fostering a culture of continuous improvement.

Ryan K. Stansfield is a seasoned leader with over 23 years of experience in small molecule drug discovery and development. Currently serving as Director of DMPK-Toxicology at 858 Therapeutics, he has successfully led teams through critical phases of drug development, including managing IND-enabling toxicology studies and building high-performing scientific teams. Stansfield is recognized for his deep expertise in ADME, safety pharmacology, and toxicology, as well as his strategic ability to drive projects from discovery to clinical trials. Throughout his career, he has demonstrated exceptional communication skills, collaborating across functions and ensuring timely, rigorous data to support regulatory submissions. With a proven track record in managing budgets, experimental design, and in-licensing diligence, Stansfield has contributed to the successful advancement of multiple therapeutic candidates.

Excited to share my professional journey in NGS cancer diagnostics, biotech, and healthcare innovation! With over 20 years of experience spanning product management, AI-driven automation, clinical trials, and regulatory compliance, I have led multi-billion-dollar product launches and driven transformative advancements in precision medicine and oncology. My expertise in agile methodologies, strategic planning, and cross-functional leadership has enabled me to bridge science and business for impactful solutions. Here is my biography.

Raymond Chang is a seasoned Translational Imaging Scientist with over two decades of experience spanning pharmaceutical research, contract research organizations, and academic discovery. Renowned for his expertise in advanced imaging modalities such as PET, SPECT, and CT, Chang has contributed significantly to the development of preclinical disease models and innovative therapeutics. His career highlights include leading the enterprise implementation of multimodality bioinformatics systems, developing cutting-edge imaging tools, and managing GLP and Non-GLP studies that bridge preclinical and clinical research. A dedicated leader and collaborator, Chang excels in regulatory compliance, experimental design, and fostering partnerships, making him a pivotal figure in advancing personalized medicine and imaging science.

The healthcare investment landscape is undergoing a revolutionary transformation, addressing the binary risk and inefficiency that have long plagued therapeutic R&D. Traditional drug development processes are slow, costly, and fraught with failure, but advances in AI are now enabling faster, more accurate drug discovery and validation. Leveraging this potential, a novel funding model has emerged, combining insurance underwriting by Lloyd’s of London and non-dilutive lending, supported by AI-driven validation technology from GATC Health. This approach reduces risk for all stakeholders, accelerates funding timelines, and maximizes the chances of success for biotech startups. With nearly 100 startups already in the pipeline, this innovative funding vehicle promises to expedite therapeutic breakthroughs, benefiting investors, companies, and most importantly, patients in need.

Peter Payne is a highly accomplished executive with over 30 years of leadership experience in the pharmaceutical, biotechnology, and contract research organization (CRO) industries. Known for his integrity and results-driven approach, Peter has successfully led organizations through periods of significant growth and transformation. With deep expertise in drug development, clinical trials, and corporate strategy, he has built a strong reputation for driving innovation and strategic partnerships. His leadership spans notable roles, including Vice President at Optum, President of Gennaker Bio, and CEO at multiple biotech companies. Peter’s ability to communicate complex strategies and foster cross-functional collaboration has made him a respected figure in the life sciences industry.

Scott Abbott is a seasoned executive with over 26 years of experience across healthcare, tech, biotech, and pharma industries. Known for his integrity and results-driven leadership, Scott has a proven track record in business development, marketing strategy, product launches, clinical trials, and operations management. His global experience, including work in the US, Canada, and Europe, positions him as an invaluable asset for startups and established companies alike. Scott’s strategic acumen has helped numerous organizations navigate market complexities, drive growth, and achieve operational success. As a thought leader, he has authored peer-reviewed publications and shared his expertise at major industry events, always delivering clear and impactful insights.

Darren LaCour Jr. is a seasoned expert in biomedical product development, with a distinguished career focused on ensuring regulatory compliance and patient safety. His extensive knowledge in clinical trial design, execution, and oversight has been pivotal in bringing innovative medical devices to market. As a strategic leader, Darren has successfully navigated the complex processes required for U.S. regulatory approval, while also dedicating himself to educating future leaders in the field. His commitment to excellence and mentorship has made him a respected figure in both industry and academia.

I'm excited to share my journey and experiences in oncology, cancer research, and precision medicine. Over the past 32 years, I’ve had the privilege of founding and leading institutions dedicated to advancing cancer care and improving patient outcomes through innovative research and clinical trials. From my work at the Kentucky Cancer Group to my time as Director of Precision Medicine at Norton Cancer Institute, I’ve focused on integrating cutting-edge therapies and a compassionate approach to oncology. Check out my executive biography to learn more about my work and how I'm committed to pushing the boundaries of cancer care through leadership and collaboration.

I’m excited to share my professional journey and the expertise I’ve developed over 41 years in clinical research and drug development. As the President and Founder of New England Clinical Consulting (NECC), I’ve had the privilege of leading clinical operations across the biotech and pharma sectors, working on therapeutic areas ranging from oncology to infectious diseases. Throughout my career, I’ve tackled complex challenges, built high-performing teams, and delivered successful clinical trials from early-phase development to global Phase 3 studies. I’m passionate about advancing clinical research, overseeing CROs, and developing innovative drug development strategies. If you’re interested in clinical operations or collaborating on new projects, I’d love to connect and explore how we can work together to drive impactful results.

I'm excited to share my executive biography, which highlights my 40+ years of leadership experience in the biotechnology and pharmaceutical industries. Throughout my career, I've had the privilege of driving transformative change through innovative solutions, leading global strategic initiatives, and building high-performing teams. From developing groundbreaking drug delivery technologies to optimizing global supply chains, I remain passionate about helping organizations grow and succeed. I look forward to continuing my work in advisory and leadership roles, supporting impactful ventures in healthcare. Let’s connect and explore opportunities to make a difference together!

I’m excited to share a glimpse into my professional journey and achievements. With a Ph.D. in Immunology from the Hebrew University of Jerusalem and extensive experience at the National Institute of Allergy and Infectious Diseases (NIAID), I’ve had the privilege of leading transformative research in cancer immunotherapy and PET imaging of cancer biomarkers. My work has focused on advancing personalized medicine and targeted therapies, and I’m passionate about driving innovation in these fields. I invite you to explore my career highlights and contributions, which reflect my commitment to impactful research and visionary leadership. Thank you for your support and interest!

I'm excited to share the incredible journey of Dr. Nader Pouratian, whose distinguished career in neurosurgery and neuro medical technology has truly set a new benchmark in patient care and innovation. With over 20 years of expertise in deep brain stimulation, brain mapping, and clinical trials, Dr. Pouratian has made significant strides in advancing therapeutic techniques and improving patient outcomes. His roles at UT Southwestern Medical Center and UCLA Health highlight his dedication to pioneering research and personalized treatment. I'm proud to present his biography, which showcases his remarkable contributions and unwavering commitment to enhancing lives through his groundbreaking work.

I’m thrilled to share my updated executive biography, highlighting my journey and experiences in the biotech and pharma industries. With over 30 years of experience, I’ve had the privilege of leading clinical operations, managing complex programs, and working with exceptional teams to drive advancements in clinical research. My recent role as Senior Director of Clinical Operations at uniQure allowed me to deepen my expertise in clinical development, cross-functional team leadership, and strategic program management. I’m passionate about leveraging this experience to contribute to innovative projects and impactful organizations. Thank you for taking the time to read about my professional journey. I look forward to connecting and exploring new opportunities where I can bring my skills and dedication to make a difference.